The efficacy and safety of two different doses of caffeine in respiratory function of preterm infants

Fatemeh Faramarzi, Mohammadreza Shiran, Mohammadreza Rafati, Roya Farhadi, Ebrahim Salehifar, Maryam Nakhshab, Fatemeh Faramarzi, Mohammadreza Shiran, Mohammadreza Rafati, Roya Farhadi, Ebrahim Salehifar, Maryam Nakhshab

Abstract

Background: Caffeine is widely used for prevention of apnea and helps successful extubation from mechanical ventilation. It facilitates the transition from invasive to noninvasive support and reduces duration of continuous positive airway pressure (CPAP) in preterm infants. The optimum caffeine dose in preterm infants has not been well-studied in terms of benefits and risks. We compared efficacy and safety of once versus twice-daily caffeine dose in premature infants.

Methods: This study was a randomized clinical trial conducted in Bu-Ali Sina Teaching Hospital, Sari. Patients with gestational age of <37 weeks were included. Both groups received 20 mg/kg loading dose of caffeine intravenously followed by maintenance dose of 5 mg/kg/day in group 1 or 2.5 mg/kg every 12 hours in group 2. Extubation failure, CPAP failure and possibly adverse reactions were evaluated.

Results: The mean of gestational age and birth weight were 32.27±3.23 (weeks) and 1824.5±702.54 (gr), respectively. The rate of extubation and CPAP failure and length of NICU stay were lower in twice-daily-group with no statistically significant difference. The means of O2 saturations on the first three days of caffeine therapy were higher in twice-daily-group. Caffeine was generally safe and well tolerated.

Conclusions: This study, which assayed short-term effects of caffeine, showed that twice daily caffeine maintenance dose was related to more benefits in facilitating extubation or prevention of CPAP failure in preterm infants. However, there was not statistically significant difference between two groups.

Keywords: CPAP failure; Caffeine; Extubation failure; Preterm infants.

Conflict of interest statement

There is no conflict of interest.

Figures

Figure 1
Figure 1
Diagram of the participants

References

    1. Edwards MO, Kotecha SJ, Kotecha S. Respiratory distress of the term newborn infant. Paediatr Respir Rev. 2013;14:29–37.
    1. Subiramanian S, Sweet DG. Management of neonatal respiratory distress syndrome. Paediatr Child Health. 2012;22:518–22.
    1. Sweet DG, Carnielli V, Greisen G, et al. European consensus guidelines on the management of respiratory distress syndrome-2016 update. Neonatology. 2016;111:107–25.
    1. Wielenga JM, van den Hoogen A, et al. Protocolized versus non‐protocolized weaning for reducing the duration of invasive mechanical ventilation in newborn infants. Cochrane Database Syst Rev. 2016;3:CD011106.
    1. Steer P, Flenady V, Shearman A, et al. High dose caffeine citrate for extubation of preterm infants: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed. 2004;89:F499–503.
    1. Baird TM, Martin RJ, Abu-Shaweesh JM. Clinical associations, treatment, and outcome of apnea of prematurity. NeoReviews. 2002;3:e66–70.
    1. Bhatia J. Current options in the management of apnea of prematurity. Clin Pediatr. 2000;39:327–36.
    1. Henderson-Smart DJ, Davis PG. Prophylactic methylxanthines for extubation in preterm infants. Cochrane Database Syst Rev. 2003;1:CD000139.
    1. Aranda JV, Beharry K, Valencia GB, Natarajan G, Davis J. Caffeine impact on neonatal morbidities. J Matern Fetal Neonatal Med. 2010;23:20–3.
    1. Kassim Z, Greenough A, Rafferty GF. Effect of caffeine on respiratory muscle strength and lung function in prematurely born, ventilated infants. Eur J Pediatr. 2009;168:1491–5.
    1. Kraaijenga JV, Hutten GJ, de Jongh FH, van Kaam AH. The effect of caffeine on diaphragmatic activity and tidal volume in preterm infants. J Pediatr. 2015;167:70–5.
    1. Comer AM, Perry CM, Figgitt DP. Caffeine citrate. Paediatr Drugs. 2001;3:61–79.
    1. Henderson-Smart DJ, De Paoli AG. Methylxanthine treatment for apnoea in preterm infants. Cochrane Database Syst Rev. 2010;12:CD000140.
    1. Schmidt B, Roberts RS, Davis P, et al. Caffeine therapy for apnea of prematurity. N Engl J Med. 2006;354:2112–21.
    1. Schmidt B, Anderson PJ, Doyle LW, et al. Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. JAMA. 2012;307:275–82.
    1. Bancalari E. Caffeine for apnea of prematurity. N Engl J Med. 2006;354:2179–81.
    1. Schmidt B, Roberts RS, Davis P, et al. Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med. 2007;357:1893–902.
    1. Mueni E, Opiyo N, English M. Caffeine for the management of apnea in preterm infants. Int Health. 2009;1:190–5.
    1. Johnson P. Caffeine citrate therapy for apnea of prematurity. Neonatal Netw. 2011;30:408–12.
    1. Orozco-Gregorio H, Mota-Rojas D, Villanueva D, et al. Caffeine therapy for apnoea of prematurity: Pharmacological treatment. Afr J Pharm Pharmacol. 2011;5:564–7.
    1. Johnson T. Benefits of caffeine citrate: neurodevelopmental outcomes of ELBW infants. Available at: 2011. .
    1. Pacifici GM. Clinical pharmacology of caffeine citrate in preterm infants. MedicalExpress. 2014;1:243–50.
    1. Abdel-Hady H, Nasef N, Shabaan AE, Nour I. Caffeine therapy in preterm infants. World J Clin Pediatr. 2015;4:81–93.
    1. Lista G, Fabbri L, Polackova R, et al. The real-world routine use of caffeine citrate in preterm infants: a European postauthorization safety study. Neonatology. 2016;109:221–7.
    1. Aranda JV, Cook CE, Gorman W, et al. Pharmacokinetic profile of caffeine in the premature newborn infant with apnea. J Pediatr. 1979;94:663–8.
    1. Aranda JV, Gorman W, Bergsteinsson H, Gunn T. Efficacy of caffeine in treatment of apnea in the low-birth-weight infant. J Pediatr. 1977;90:467–72.
    1. Hoecker C, Nelle M, Beedgen B, et al. Effects of a divided high loading dose of caffeine on circulatory variables in preterm infants. Arch Dis Childhood Fetal Neonatal Ed. 2006;91:F61–4.
    1. Mohammed S, Nour I, Shabaan AE, et al. High versus low-dose caffeine for apnea of prematurity: a randomized controlled trial. Eur J Pediatr. 2015;174:949–56.
    1. Romagnoli C M, De Carolis, U Muzii, et al. Effectiveness and side effects of two different doses of caffeine in preventing apnea in premature infants. Ther Drug Monit. 1992;14:14–19.
    1. Steer PA, Flenady VJ, Shearman A, et al. Periextubation caffeine in preterm neonates: a randomized dose response trial. J Paediatr Child Health. 2003;39:511–15.
    1. Zhao Y, Tian X, Liu G. Clinical effectiveness of different doses of caffeine for primary apnea in preterm infants. Zhonghua Er Ke Za Zhi. 2016;54:33–6.
    1. Dobson NR, Hunt CE. Pharmacology review: caffeine use in neonates: indications, pharmacokinetics, clinical effects, outcomes. NeoReviews. 2013;14:e540–e50.
    1. Gare S, Lal M, Tin W. Apnoea in premature infants and caffeine therapy. Infant. 2013;9:9–12.
    1. Gunn TR, Metrakos K, Riley P, Willis D, Aranda JV. Sequelae of caffeine treatment in preterm infants with apnea. J Pediatr. 1979;94:106–9.
    1. Murat I, Moriette G, Blin M, et al. The efficacy of caffeine in the treatment of recurrent idiopathic apnea in premature infants. J Pediatr. 1981;99:984–9.
    1. Aranda JV, Turmen T, Davis J, et al. Effect of caffeine on control of breathing in infantile apnea. J Pediatr. 1983;103:975–9.
    1. Anwar M, Mondestin H, Mojica N, et al. Effect of caffeine on pneumogram and apnoea of infancy. Arch Dis Child. 1986;61:891–5.
    1. Gray PH, Flenady VJ, Charles BG, Steer PA. Caffeine Collaborative Study Group Caffeine citrate for very preterm infants: effects on development, temperament and behaviour. J Paediatr Child Health. 2011;47:167–72.
    1. Rhein LM, Dobson NR, Darnall RA, et al. Effects of caffeine on intermittent hypoxia in infants born prematurely: a randomized clinical trial. JAMA Pediatr. 2014;168:250–7.
    1. Armanian AM, Iranpour R, Faghihian E, Salehimehr N. Caffeine administration to prevent apnea in very premature infants. Pediatr Neonatol. 2016;57:408–12.
    1. Lodha A, Seshia M, McMillan DD, et al. Association of early caffeine administration and neonatal outcomes in very preterm neonates. JAMA Pediatr. 2015;169:33–8.
    1. Parikka V, Beck J, Zhai Q, et al. The effect of caffeine citrate on neural breathing pattern in preterm infants. Early Hum Dev. 2015;91:565–8.
    1. Yu M, Huang JH, Zhu R, et al. Effect of caffeine citrate on early pulmonary function in preterm infants with apnea. Zhongguo Dang Dai Er Ke Za Zhi. 2016;18:206–10.
    1. Erenberg A, Leff RD, Haack DG, et al. Caffeine citrate for the treatment of apnea of prematurity: a double‐blind, placebo‐controlled study. Pharmacotherapy. 2000;20:644–52.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅